Axsome Therapeutics (AXSM) Cash & Current Investments (2015 - 2026)
Axsome Therapeutics recorded quarterly Cash & Current Investments of $305.1 million in Q1 2026, down 5.52% quarter-over-quarter from $322.9 million in Q4 2025, and up 1.4% year-over-year from $300.9 million in Q1 2025.
Axsome Therapeutics' Cash & Current Investments history runs 12 years deep, the most recent figure standing at $305.1 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 1.4% year-over-year to $305.1 million; the TTM figure through Mar 2026 stood at $305.1 million (up 1.4% YoY), while the FY2025 annual figure was $322.9 million, up 2.4% from the prior year.
- Cash & Current Investments came in at $305.1 million for Q1 2026 at Axsome Therapeutics, down from $322.9 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $437.1 million in Q2 2023 to a low of $73.4 million in Q2 2022.
- A 5-year average of $289.4 million and a median of $315.4 million in 2024 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments sank 48.56% in 2022 and surged 495.57% in 2023, its largest moves.
- Axsome Therapeutics' Cash & Current Investments stood at $200.8 million in 2022, then surged by 92.29% to $386.2 million in 2023, then retreated by 18.34% to $315.4 million in 2024, then gained by 2.4% to $322.9 million in 2025, then dropped by 5.52% to $305.1 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $305.1 million, $322.9 million, and $325.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | 305.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 305.10 Mn |
| Dec 31, 2025 | 322.93 Mn |
| Sep 30, 2025 | 325.30 Mn |
| Jun 30, 2025 | 303.02 Mn |
| Mar 31, 2025 | 300.90 Mn |
| Dec 31, 2024 | 315.35 Mn |
| Sep 30, 2024 | 327.30 Mn |
| Jun 30, 2024 | 315.66 Mn |
| Mar 31, 2024 | 331.44 Mn |
| Dec 31, 2023 | 386.19 Mn |
| Sep 30, 2023 | 416.60 Mn |
| Jun 30, 2023 | 437.11 Mn |
| Mar 31, 2023 | 246.50 Mn |
| Dec 31, 2022 | 200.84 Mn |
| Sep 30, 2022 | 227.52 Mn |
| Jun 30, 2022 | 73.39 Mn |
| Mar 31, 2022 | 84.70 Mn |
| Dec 31, 2021 | 86.47 Mn |
| Sep 30, 2021 | 114.60 Mn |
| Jun 30, 2021 | 141.22 Mn |
| Mar 31, 2021 | 164.66 Mn |
| Dec 31, 2020 | 183.88 Mn |
| Sep 30, 2020 | 202.36 Mn |
| Jun 30, 2020 | 190.68 Mn |
| Mar 31, 2020 | 197.31 Mn |
| Dec 31, 2019 | 219.97 Mn |
| Sep 30, 2019 | 43.64 Mn |
| Jun 30, 2019 | 53.75 Mn |
| Mar 31, 2019 | 42.62 Mn |
| Dec 31, 2018 | 13.97 Mn |
| Sep 30, 2018 | 15.22 Mn |
| Jun 30, 2018 | 20.35 Mn |
| Mar 31, 2018 | 26.63 Mn |
| Dec 31, 2017 | 34.02 Mn |
| Sep 30, 2017 | 31.67 Mn |
| Jun 30, 2017 | 37.99 Mn |
| Mar 31, 2017 | 45.02 Mn |
| Dec 31, 2016 | 36.62 Mn |
| Sep 30, 2016 | 33.89 Mn |
| Jun 30, 2016 | 38.75 Mn |
| Mar 31, 2016 | 44.08 Mn |
| Dec 31, 2015 | 48.04 Mn |
| Sep 30, 2015 | 4.62 Mn |
| Jun 30, 2015 | 6.41 Mn |
| Mar 31, 2015 | 1.69 Mn |